Disclosures for "Eptinezumab Treatment was Associated with Longer Interictal Periods and Larger Improvements in Quality of Life Than Placebo in Participants with Migraine for Whom 2-4 Prior Preventive Treatments had Failed: A Post Hoc Analysis of the DELIVER Trial"